Calvet A, Díez de Ulzurrun M, Pérez M T, Esteras J
Aten Primaria. 2001 Jan;27(1):33-7. doi: 10.1016/s0212-6567(01)78770-7.
To identify the pharmacological interactions of clinical relevance (PICR) in the medication authorization cards (MAC) of the chronically ill and to establish strategies to minimise their appearance.
Cross-sectional descriptive study.
Rural primary care centre.
Random sample of 626 MAC out of a total of 1306.
In December 1998, the following was gathered for every MAC with more than one drug treatment: age, sex, number of drugs, intrinsic value, drugs prescribed, daily dose and pharmacological interactions (PI), classified (using the scale of Hansten 1996) into light and clinically relevant.
Mantel-Haenszel (alpha = 0.05). Patients' mean age was 69.1 (95% CI, +/- 1.2). Mean number of drugs per MAC was 4 (95% CI, +/- 0.2). 341 PI affecting 197 patients (31.5%, 95% CI, +/- 3.6) were identified. 24.9% (95% CI, +/- 4.5) were PICR, detected in 11.7% (95% CI, +/- 2.5) of the MAC. The existence of PI was related to the number of drugs prescribed to each patient (p < 0.01). There were 26 PI with drugs of low intrinsic value (7.6%; 95% CI, +/- 2.8). 74.1% (95% CI, +/- 9.3) of the total PICR could be avoided by simple recommendations; and the remaining 25.9% (95% CI, +/- 9.3) by monitoring and follow-up of patients.
It is important to identify the medications most commonly involved in the PICR so as to establish corrective measures to minimise the risks arising from multiple medication. Four educational messages advise on over 60% of the PICR detected.
确定慢性病患者用药授权卡(MAC)中具有临床相关性的药物相互作用(PICR),并制定策略以尽量减少其出现。
横断面描述性研究。
农村初级保健中心。
从总共1306份MAC中随机抽取626份样本。
1998年12月,针对每份使用多种药物治疗的MAC收集了以下信息:年龄、性别、药物数量、内在价值、所开药物、每日剂量以及药物相互作用(PI),并根据汉斯坦1996年的量表将其分为轻度和具有临床相关性。
Mantel-Haenszel检验(α = 0.05)。患者的平均年龄为69.1岁(95%可信区间,±1.2)。每份MAC的平均药物数量为4种(95%可信区间,±0.2)。共识别出341种影响197名患者的PI(31.5%,95%可信区间,±3.6)。24.9%(95%可信区间,±4.5)为PICR,在11.7%(95%可信区间,±2.5)的MAC中检测到。PI的存在与每位患者所开药物的数量相关(p < 0.01)。有26种与低内在价值药物相关的PI(7.6%;95%可信区间,±2.8)。通过简单建议可避免74.1%(95%可信区间,±9.3)的PICR;其余25.9%(95%可信区间,±9.3)通过对患者的监测和随访来避免。
识别最常涉及PICR的药物非常重要,以便制定纠正措施,将多重用药带来的风险降至最低。四条教育信息涵盖了检测到的60%以上的PICR。